Magnetic targeting of novel heparinized iron oxide nanoparticles evaluated in a 9l-glioma mouse model

Pharmaceutical Research

Volumn 31, Issue 3, 2014, Pages 579-592

  Zhang, Jian ^a,b   Shin, Meong Cheol ^a,b   Yang, Victor C ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

9L glioma; heparin; iron oxide nanoparticles; magnetic resonance imaging; magnetic targeting

Indexed keywords

DRUG CARRIER; HEPARIN; MACROGOL; PEGYLATED AND HEPARINIZED MAGNETIC IRON OXIDE NANOPARTICLE; PROTAMINE; UNCLASSIFIED DRUG;

ANALYTICAL EQUIPMENT; ANIMAL EXPERIMENT; ANIMAL IMAGING SYSTEM; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CROSS LINKING; DRUG TARGETING; ELECTRON SPIN RESONANCE; GLIOMA; IN VIVO STUDY; INFRARED SPECTROSCOPY; LIVER; MAGNETIC TARGETING; MALE; MOLECULAR STABILITY; MOUSE; MOUSE MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PHYSICAL CHEMISTRY; PLASMA HALF LIFE; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; SPLEEN; SUPERCONDUCTING QUANTUM INTERFERENCE DEVICE; TRANSMISSION ELECTRON MICROSCOPY; TUMOR LOCALIZATION; TUMOR MODEL;

ANIMALS; DRUG DELIVERY SYSTEMS; FERRIC COMPOUNDS; GLIOMA; HEPARIN; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C57BL; NANOPARTICLES; POLYETHYLENE GLYCOLS; PROTAMINES;

EID: 84895502718     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1182-5     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics 2013. CA-Cancer J Clin. 2013;63(1):11-30.
2. Lindley C, McCune J, Thomason T, Lauder D, Sauls A, Adkins S, et al. Perception of chemotherapy side effects. Cancer Pratc. 1999;7(2):59-65.
3. Lee JH, Lee K, Moon SH, Lee YH, Park TG, Cheon J. All-in-One target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew Chem. 2009;121(23):4238-43.
4. Liu Z, Winters M, Holodniy M, Dai HJ. siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. Angew Chem. 2007;46(12):2023-7.
5. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654-70.
6. Zhou XK, Qiu J, Wang Z, Huang NY, Li XL, Li Q, et al. In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin. J Cancer Res Clin Oncol. 2012;138(7):1081-90.
7. Cao Y, Marks JW, Liu Z, Cheung LH, Hittelman WN, Rosenblum MG. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies. Oncogene. 2013;32(4):1-11.
8. Wang JT, Giuntini F, Eggleston IM, Bown SG, MacRobert AJ. Photochemical internalisation of a macromolecular protein toxin using a cell penetrating peptide-photosensitiser conjugate. J Control Release. 2012;157(2):305-13.
9. Park YJ, Chang LC, Liang JF, Moon C, Chung CP, Yang VC. Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. Faseb J. 2005;19(11):1555-7.
10. Kwon YM, Li YT, Naik S, Liang JF, Huang YZ, Park YJ, et al. The ATTEMPTS delivery systems for macromolecular drugs. Expert Opin Drug Del. 2008;5(11):1255-66.
11. Sawant RM, Hurley JP, Salmaso S, Kale A, Tolcheva E, Levchenko TS, et al. "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem. 2006;17(4):943-9.
12. Winer I, Wang S, Lee YE, Fan W, Gong Y, Burgos-Ojeda D, et al. F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo. Cancer Res. 2010;70(21):8674-83.
13. Xie J, Liu G, Eden HS, Ai H, Chen XY. Surface-engineered magnetic nanoparticle platforms for cancer imaging and therapy. Accounts Chem Res. 2011;44(10):883-92.
14. Reddy LH, Arias JL, Nicolas J, Couvreur P. Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem Rev. 2012;112(11):5818-78.
15. Yoo DW, Lee JH, Shin TH, Cheon JW. Theranostic magnetic nanoparticles. Accounts Chem Res. 2011;44(10):863-74.
16. Colombo M, Carregal-Momero S, Casula MF, Gutierrez L, Morales MP, Bohm IB, et al. Biological applications of magnetic nanoparticles. Chem Soc Rev. 2012;41(11):4306-34.
17. Lee SM, Song Y, Hong BJ, MacRenaris KW, Mastarone DJ, O'Halloran TV, et al. Modular polymer-caged nanobins as a theranostic platform with enhanced magnetic resonance relaxivity and pH-responsive drug release. Angew Chem. 2010;122(51):10156-60.
18. Sanson C, Diou O, Thevenot J, Ibarboure E, Soum A, Brulet A, et al. Doxorubicin loaded magnetic polymersomes: theranostic nanocarriers for MR imaging and magneto-chemotherapy. ACS Nano. 2011;5(2):1122-40.
19. Chertok B, David AE, Yang VC. Magnetically-enabled and MR-monitored selective brain tumor protein delivery in rats via magnetic nanocarriers. Biomaterials. 2011;32(26):6245-53.
20. Sun CR, Du K, Fang C, Bhattarai N, Veiseh O, Kievit F. PEG-mediated synthesis of highly dispersive multifunctional superparamagnetic nanoparticles: their physicochemical properties and function in vivo. ACS Nano. 2010;4(4):2402-10.
21. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliver Rev. 2011;63(3):131-5.
22. Simkovic I, Laszlo JA, Thompson AR. Preparation of a weakly basic ion exchanger by crosslinking starch with epichlorohydrin in the presence of NHAOH. Carbohyd Polym. 1996;30(1):25-30.
23. Pittet MJ, Swirski FK, Reynolds F, Josephson L, Weissleder R. Labeling of immune cells for in vivo imaging using magnetofluorescent nanoparticles. Nat Protoc. 2006;1(1):73-9.
24. Prochazkova S, Varum KM, Østgaard K. Quantitative determination of chitosans by ninhydrin. Carbohyd Pllym. 1999;38(2):115-22.
25. Skoog B. Determination of polyethylene glycols 4000 and 6000 in plasma protein preparations. Vox Sanguinis. 1979;37(6):345-9.
26. Kurfurst MM. Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal Chem. 1992;200(2):244-8.
27. Ma SC, Fu B, Meyerhoff ME, Yang VC. Electrochemical sensor for heparin: further characterization and bioanalytical applications. Anal Chem. 1993;65(15):2078-84.
28. Chertok B, David AE, Yang VC. Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. Biomaterials. 2010;31(24):6317-24.
29. Cole AJ, David AE, Wang JX, Galban CJ, Hill HL, Yang VC. Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles. Biomaterials. 2011;32(26):2183-93.
30. Richter H, Kettering M, Wiekhorst F, Steinhoff U, Hilger I, Trahms L. Magnetorelaxometry for localization and quantification of magnetic nanoparticles for thermal ablation studies. Phys Med Biol. 2010;55(3):624-34.
31. Xie J, Xu C, Kohler N, Hou Y, Sun S. Controlled PEGylation of monodisperse Fe3O4 nanoparticles for reduced non-specific uptake by macrophage cells. Adv Mater. 2007;19(20):3163-6.
32. Singh S, Wu BM, Dunn JCY. The enhancement of VEGF-mediated angiogenesis by polycaprolactone scaffolds with surface cross-linked heparin. Biomaterials. 2011;32(8):2059-69.